NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow NBP
NovaBridge Biosciences (NBP) EV/Sales
As of 16 October 2026, NovaBridge Biosciences (NBP) trades at a EV/Sales of −3.8×. Over the past ten years it has ranged from −17.5× (February 2020) to 457× (September 2020); the current reading is higher than 33% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −5.6× | — |
| FY2022 | −0.6× | — |
| FY2021 | 12.4× | (7.68%) |
| FY2020 | 13.4× | — |
| FY2019 | −16.6× | — |
| FY2018 | −16.6× | — |
| FY2017 | −16.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | −14.8× | — |
| Jun 2023 | −6.8× | — |
| Jun 2022 | 1.4× | (88.63%) |
| Dec 2021 | 12.4× | (45.80%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NBP NovaBridge Biosciences | −3.8× |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| MENS Jyong Biotech Ltd. compare | n/m |
| CDXS Codexis, Inc. compare | 1.2× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.2× |
| MDWD MediWound Ltd. compare | 10.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)